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Abstract
Background: Estrogen Receptor alpha (ERα)-positive breast cancer patients receive endocrine therapy, often in
the form of tamoxifen. However, resistance to tamoxifen is frequently observed. A signalling cascade that
leads to tamoxifen resistance is dictated by activation of the Protein Kinase A (PKA) pathway, which leads to
phosphorylation of ERα on Serine 305 and receptor activation, following tamoxifen binding. Thus far, it remains elusive
what protein complexes enable the PKA-ERα interaction resulting in ERα Serine 305 phosphorylation.
Methods: We performed immunohistochemistry to detect ERαSerine 305 phosphorylation in a cohort of breast cancer
patients who received tamoxifen treatment in the metastatic setting. From the same tumor specimens, Agilent 44 K
gene expression analyses were performed and integrated with clinicopathological data and survival information. In vitro
analyses were performed using MCF7 breast cancer cells, which included immunoprecipitations and Fluorescence
Resonance Energy Transfer (FRET) analyses to illustrate ERα complex formation. siRNA mediated knockdown experiments
were performed to assess effects on ERαSerine 305 phosphorylation status, ERα/PKA interactions and downstream
responsive gene activity.
Results: Stratifying breast tumors on ERα Serine 305 phosphorylation status resulted in the identification of a gene
network centered upon AKAP13. AKAP13 mRNA expression levels correlate with poor outcome in patients who received
tamoxifen treatment in the metastatic setting. In addition, AKAP13 mRNA levels correlate with ERαSerine 305
phosphorylation in breast tumor samples, suggesting a functional connection between these two events. In a luminal
breast cancer cell line, AKAP13 was found to interact with ERα as well as with a regulatory subunit of PKA. Knocking
down of AKAP13 prevented PKA-mediated Serine 305 phosphorylation of ERα and abrogated PKA-driven tamoxifen
resistance, illustrating that AKAP13 is an essential protein in this process.
Conclusions: We show that the PKA-anchoring protein AKAP13 is essential for the phosphorylation of ERαS305, which
leads to tamoxifen resistance both in cell lines and tamoxifen-treated breast cancer patients.
Background
Breast cancer is the most frequently diagnosed malig-
nancy in women. Since 75 % of all breast tumors ex-
press Estrogen Receptor alpha (ERα), tumor growth is
considered to be dependent on the activity of this
hormone-induced transcription factor. Thereby, treat-
ment is focused on inhibiting the function of ERα. One
of the most frequently prescribed drugs in endocrine
treatment is tamoxifen. Tamoxifen competes with ERα’s
natural ligand estradiol for binding to the ligand-binding
pocket of the receptor. Tamoxifen forces the receptor in
an alternative conformation as compared to estradiol,
thereby preventing recruitment of coregulators to the
complex, which are essential for ERα-driven transcription
[1]. Although tamoxifen is considered a highly successful
drug, resistance to treatment is common. Resistance to
tamoxifen treatment can occur through a multitude of
mechanisms, including activation of the MAP kinase
pathway [2–4] or overexpression of PAK1 [5], SRC1 [6],
SRC3 [7] and ErbB2 [8].
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An alternative mechanism of tamoxifen resistance is me-
diated by activation of the Protein Kinase A (PKA) path-
way [9]. Decreased expression of a regulatory component
of the PKA complex, PKA-RIα, was found to correlate with
a non-favorable prognosis in breast cancer patients treated
with tamoxifen [10]. We could confirm these data [9], and
found in vitro that PKA-RIα knockdown enhances breast
cancer cell proliferation in the presence of tamoxifen. In
addition, we showed in the same study that the major site
PKA-responsive phosphorylation site on ERα is a serine
residue found at position 305. This phosphorylation leads
to a conformational arrest within the receptor and results
in an agonistic response of the otherwise inhibitory com-
pound tamoxifen. In this altered conformation ERα re-
orientates its C-terminus towards its coactivators, which
prevents a dissociation of RNA Polymerase II from the
complex that is normally observed in tamoxifen treated
cells, thereby resulting in transcriptional activation in the
presence of tamoxifen [11]. PKA-stimulated MCF-7 breast
cancer cells express a unique repertoire of genes that are
differentially expressed as compared to tamoxifen or PKA-
activating cAMP treatment alone. [12] This potentially un-
derlies a cell biological response for this pathway to tam-
oxifen resistance. In accordance, we recently reported S305
phosphorylated ERα to bind a unique set of promoters
regulating transcriptional programs involved in tamoxifen
resistance [13].
In addition to in vitro data, in breast cancer patients
treated with tamoxifen for metastatic disease, the phos-
phorylation status of ERαS305 was found to be indicative
for poor outcome [14]. Moreover, ERαS305 phosphoryl-
ation was found to be a predictive marker for tamoxifen re-
sistance in pre- [14, 15] and postmenopausal patients [16].
However, it remains elusive what regulates the ERα/PKA
interaction, which is an essential step in the ERαS305
phosphorylation pathway.
PKA is a multi-protein complex. The inactivated PKA
complex is composed of a catalytic subunit (PKAcat) that
associates, in an inactive state, to its regulatory subunits
(PKA-RI and RII). After the regulatory subunits bind
cAMP, the catalytic subunit can dissociate from the com-
plex to phosphorylate its substrates. There are many known
PKA targets, and in order to achieve substrate-specificity,
PKA activity needs to be locally confined. Localized PKA
activation can occur in multiple ways. Intracellularly, cAMP
levels are unevenly and dynamically distributed, [17, 18]
which can partly be explained by the tethering of phospho-
diesterases (PDEs) at distinct subcellular domains [19–21].
Alternatively, PKA activity can be locally confined by A-
kinase anchoring proteins (AKAPs). The regulatory
subunits of PKA can interact with AKAP family members,
which determine the subcellular localization of the PKA
complex. Next to associating with PKA subunits, AKAPs
can also physically interact with the PKA substrates. This
way, activated PKA can act locally and directly on its sub-
strates, thereby orchestrating substrate specificity. AKAPs
possess a PKA-anchoring domain composed of a 14–18
residue long amphipathic helix [22], by which they interact
with a hydrophobic groove formed by 4 alpha-helical struc-
tures on the PKA-RII subunit [23–26]. At least 50 AKAPs
have been identified, with varying expression levels among
different tissues and with their own unique intracellular
localizations [27]. A number of these AKAPs have been
reported to correlate with the occurrence of different can-
cer subtypes, including AKAP3 (ovarian cancer) [28, 29],
AKAP4 (multiple myeloma) [30], AKAP9 (breast cancer)
[31], AKAP10 (breast cancer) [32] and AKAP13 (colorec-
tal cancer [33] and breast cancer [34]). Thus far, it remains
unknown which AKAP family member is responsible for
enabling the PKA-induced phosphorylation of Serine 305
on ERα, resulting in tamoxifen resistance.
Here, we studied the enrichment of PKA-associated mo-
lecular pathways in a cohort of breast cancer patients,
which received tamoxifen in a metastatic setting. Stratify-
ing tumors on ERαS305 phosphorylation status resulted in
the identification of a molecular pathway involving
AKAP13, suggesting a functional link between AKAP13
levels and PKA-induced ERα phosphorylation. AKAP13
expression levels correlated with a poor outcome after
tamoxifen treatment in breast cancer patients and corre-
lated with ERαS305 phosphorylation status. In vitro experi-
ments could illustrate that AKAP13 interacts with ERα as
well as the regulatory subunit of PKA, and that AKAP13
expression is essential for PKA-induced ERαS305 phos-
phorylation. In summary, we demonstrate here that the
PKA-mediated phosphorylation of ERα at Serine 305,
which leads to tamoxifen resistance, requires the PKA-
anchoring protein AKAP13.
Methods
Tissue culture, plasmids, antibodies, shRNA and siRNA
MCF-7 cells were cultured in DMEM medium, supple-
mented with 8 % fetal-bovine serum and standard antibi-
otics. The following antibodies were used: AKAP13 (Bethyl
A301-404A-1), ERα (Santa Cruz sc-543), ERαS305P
(Millipore, clone 124.9.4), PKA RII (Abcam ab57414), PKA
catalytic-α (Cell Signalling 4782), beta-actin (Abcam,
ab8229) and AKAP95 (Bethyl, A301-061A). 3 days prior to
cell biological analyses, cells were switched to phenol-red
free DMEM, supplemented with 5 % charcoal-treated
serum. For siRNA targeting of AKAP13 and AKAP95, a
smartpool of four unique siRNAs was applied (Thermo
Scientific Dharmacon) using the manufacturers’ protocols.
Cells were subsequently cultured for 72 h on hormone-
deprived phenol-red free DMEM. The expression vector
for ERα-CFP was previously described [9]. The expression
vectors encoding for the regulatory subunit and the
YFP-tagged catalytic subunit of PKA were a kind gift from
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dr. Kees Jalink (NKI). shRNAs were provided by the NKI
robotics and screening core facility.
Cell proliferation assays
MCF-7 cells were switched into phenol-red free DMEM
supplemented with 5 % charcoal-treated serum. After 24 h,
cells were transfected with siAKAP13, siAKAP95 or siCntrl.
After 2 days the cells were seeded in 48 well plates at a
density of 104 cells/ well in phenol-red free DMEM, supple-
mented with 5 % charcoal-treated serum. Compounds were
introduced the following day and cells were allowed to
grow in the presence of the compounds for 2 weeks. The
compounds tested were 17β-estradiol (10−8 M), 4-OH-
tamoxifen (10−7 M) and Fulvestrant (10−7 M), while incuba-
tion in the presence of vehicle alone (DMSO) was used as a
control. After 2 weeks cells were fixed with methanol and
stained by a 0.2 % crystal violet solution. Finally, the dye
was solubilized in a weak acetic acid solution and the
optical density measured at 590 nm using the Infinite®
200 reader (TECAN). Alternatively, growth was assessed by
MTT using the manufacturers recomendations (Sima-
Aldrich).
Immunohistochemistry
For immunohistochemistry, tissue microarrays (TMAs)
were used from formalin fixed-paraffin-embedded tumor
tissue. Antigen retrieval was performed using citrate buf-
fer citrate buffer (10 mM, pH 6.0). Citrate buffer was
pre-heated and slides were subsequently added for
15 min (microwave 300 W). The ERαS305P antibody
staining was performed overnight in 1:20 dilution
(Millipore # 124-9-4). No lower cut-off for positivity
was applied, and any ERαS305 positive signal in the
entire slide was scored as positive. This mode of scor-
ing was consistent as previously described for this
antibody [14, 35].
Immunoprecipitaion
MCF-7 cells were grown in DMEM until ~40 % con-
fluency was achieved. Cells were subsequently hormone
depleted by culturing in heat inactivated charcoal-
treated serum-containing medium for 3–4 days to block
all ERα activity. Prior to immunoprecipitation, cells were
washed and lysed according to standard protocols. Im-
munoprecipitation was performed overnight with anti
PKA RII, AKAP13, ERα or negative control anti FLAG-
M2 (Sigma). Thereafter, the beads were washed and pre-
pared for Western blot analysis.
Quantitative RT-PCR
For quantitative RT-PCR analyses, cells were seeded in
12 well plates and hormone-deprived for 3 days. After
six hours of hormonal treatment, RNA was isolated
using Trizol (Life Technologies) using the manufacturers
protocols. cDNA was generated using SuperScript III
(Life Technologies) using the manufacturers protocols.
Primers used for QPCR were for XBP1 (GGGAAGGGC
ATTTGAAGAAC (FWD); ATGGATTCTGGCGGTAT
TGA (REV)) and TFF1 (ATCGACGTCCCTCCAGAAG
A (FWD); TGGGACTAATCACCGTGCTG (REV)). As
housekeeping gene, GAPDH (GCCATCAATGACCCC
TTCAT (FWD); TGACAAGCTTCCCGTTCTCA (REV)
was used.
FRET imaging
FRET was performed using Fluorescence Lifetime Im-
aging Microscopy (FLIM) as we applied before [36]. Cells
were seeded on coverslips and mounted in bicarbonate-
buffered saline. Imaging was performed in a heated tissue
culture chamber at 37C and under 5 % CO2. FLIM experi-
ments were performed using a LEICA DM-IRE2 micro-
scope equipped with a Lambert Instruments frequency
domain lifetime attachment. CFP was excited at 430 nm.
Emission was collected at 450–490 nm using a CCD cam-
era. FLIM measurements were performed using U2Os
cells, transfected with ERα-CFP, PKA-cat-YFP and a
non-tagged PKA-regulatory subunit. Cells were co-
transfected with siAKAP13 or siControl. Calculated
CFP lifetimes were referenced to Rhodamine-G6 which
was set at 4.11 nsec, and internally calibrated using cocul-
tured CFP containing MelJuso cells for which the lifetime
was set to 2.7 nsec, as we applied before [36]. Donor FRET
efficiency (ED) was calculated as ED = 1- (lifetime cell of
interest/ lifetime reference cell). Pairwise analysis was per-
formed for each cell before and after treatment with
10 μM forskolin for 1 h, where ED under CTS conditions
was set to 1 for each experiment.
Patient series
The patient series used in this paper has been previ-
ously described in detail [15]. This study was per-
formed in accordance with the Code of Conduct of
the Federation of Medical Scientific Societies in the
Netherlands (http://www.fmwv.nl) and has been ap-
proved by the local medical ethics committee of the
Netherlands Cancer Institute. The use of anonymous
or coded left over material for scientific purposes is
part of the standard treatment agreement with pa-
tients and therefore informed consent was not re-
quired according to Dutch law [37].
For the analysis of pathway enrichment in ERαS305P
positive breast cancer patients we used a series of breast
cancer patients who were treated with tamoxifen for
metastatic disease as was previously described [14, 35]. In
brief, this cohort from The Netherlands Cancer Institute
(NKI) consists of a consecutive series of 158 breast cancer
patients, who were selected according to the following cri-
teria: 1) invasive ERα-positive breast carcinoma, 2) no
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adjuvant systemic treatment, 3) development of relapse
before 2002, for which first-line tamoxifen mono-therapy
was given. Tamoxifen was administered according to the
national guidelines of that time. Of this series gene expres-
sion data and IHC data on ERαS305P were available for
58 tumors. For the analyses of AKAP13 levels in patients,
we used the same NKI series. Agilent 44 K array gene ex-
pression data was available for 66 patients. In addition, we
used gene-expression data available for a second cohort,
from the Erasmus Medical Centre (EMC) [38]. This EMC
cohort consists of 112 patients with primary operable, in-
vasive, ERα–positive breast cancer, diagnosed between
1981 and 1992, who developed disease recurrence and
were treated with tamoxifen as first-line treatment. For
the EMC series, Agilent 44 K array gene expression data
were available for 40 patients. For all gene expression ana-
lyses, data from both cohorts were combined. For IHC
analyses, only the NKI samples were used.
Gene expression analysis
The analysis for pathway enrichment in ERαS305P
positive patients and Agilent 44K data was previ-
ously described [35]. Data analyses were performed
using BRB array tools (version 3.6). First, using the
gene set expression comparison tool, 302 pathways
(as defined by Biocarta) were analyzed. The evaluation of
pathways that are differentially expressed between
ERαS305P positive and ERαS305P negative samples was
done using a functional class scoring analysis as previously
described [35]. Fisher’s Least Square (LS) summary statis-
tic (10,000 permutations) was used to test which pathways
were differentially expressed in ERαS305P-positive tu-
mors. First, a P-value was computed for each gene in a
pathway. Then the set of P-values for a pathway was sum-
marized by the LS summary statistics. For a set of N
genes, the LS summary statistic (LS = ∑Ni=1 (−log(pi))/N)
was defined as the mean negative natural logarithm of the
P-values of the appropriate single gene univariate test.
Second, we related the pathways to PKA using the Cancer
Genome Anatomy Project (http://cgap.nci.nih.gov/Genes/
GeneFinder) and 27 pathways out of the 302 were found
to be related to PKA. Next, we tested whether the list of
significant pathways as defined by the LS statistic
(P < 0.05) was enriched for PKA-related pathways using
Fisher’s Exact test.
Statistics
Time to tumour progression (TTP) was considered the
primary endpoint measured from the start of tamoxifen
administration and until treatment was ended because
of tumour progression. TTP was estimated according to
the Kaplan–Meier method for four different AKAP13
probes, segmenting the continuous variable in two
groups (low and high) with an equal number of events.
In addition we tested the four different AKAP13 probes for
trend, using the significance of the coefficient for the con-
tinuous AKAP13 variable. For the probe with the most sig-
nificant test for trend, we compared TTP in the NKI
cohort for two subgroups (low and high) by uni- and multi-
variate Cox proportional hazards regression. Clinico-
pathological characteristics (only available for NKI cohort)
according to AKAP13 levels were compared using Fisher’s
exact, Mann-Witney U test and the Chi square test for
trend. Data were analyzed using SPSS 15.0.
Results
AKAP pathway enrichment in ERαS305-P positive breast
cancer patients
Serine 305 phosphorylation on ERα was found to be a
predictive marker for tamoxifen resistance in breast can-
cer patients [14, 15]. To define which cell biological fac-
tors may be causally involved in the PKA-induced
phosphorylation of ERαS305, we performed pathway en-
richment analyses from a cohort of breast cancer pa-
tients, which received tamoxifen for metastatic disease
[14, 15]. The samples were stained for ERαS305P and
scored for positivity by immunohistochemistry (Fig. 1a).
Available expression array data [15] was reanalyzed
using Biocarta pathway analysis. Among the 19 pathways
differentially and significantly enriched in these two pa-
tient groups, five were found to be PKA-related. The top
two differentially regulated pathways involved AKAP13
and AKAP95 signaling cascades. Since both of these
proteins are members of the PKA-anchoring protein
family, PKA-substrate specificity regulated by AKAP
levels may be causally linked with ERαS305 phosphoryl-
ation status, and thus tamoxifen resistance.
AKAP13 interacts with ERα and PKA-RII and is essential
for PKA-mediated S305 Phosphorylation of ERα
Since AKAP13 and AKAP95 signaling cascades were sig-
nificantly enriched in the ERαS305P positive patient sub-
group, we tested in vitro whether this enrichment also
implies a causal role for either of these two proteins in
PKA-mediated ERα Serine 305 phosphorylation. siRNA-
mediated knockdown of AKAP13 and AKAP95 was
performed in MCF-7 breast cancer cells (Fig. 2a and
Additional file 1: Figure S1, respectively). Cells were
either treated or not treated with the PKA-activating
compound forskolin for 1 h prior to cell lysis. As ex-
pected and previously observed [39], PKA activation
by forskolin treatment sufficed to induce phosphoryl-
ation of ERα on Serine 305. Knocking down AKAP13
prevented the forskolin-induced increase in ERαS305P
signal, implying that AKAP13 is required for the
phosphorylation of ERα at this site. This effect was
not observed after knock down AKAP95, and Serine
305 on ERα could still be phosphorylated upon PKA
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activation (Additional file 1: Figure S1). Furthermore,
both AKAP13 as well as AKAP95 were not essential
for MCF-7 cell proliferation arrest after tamoxifen
treatment while proliferation under E2 conditions was
slightly increased (Additional file 2: Figure S2). These
data suggest that AKAP13 is not a crucial player in
normal ERα biology and tamoxifen-response in ab-
sence of PKA activation.
AKAP13 is known to be an anchoring protein of PKA,
binding both PKA-RII as well as PKA-substrates [27].
Thus, in order for AKAP13 to enable ERαS305 phos-
phorylation, it needs to interact with ERα as well as
members of the PKA complex. To illustrate such a com-
plex, we used two parallel but distinct approaches; FRET
(Fig. 2b) and co-immunoprecipitation (Fig. 2c, d, e).
FRET, or Fluorescence Resonance Energy Transfer, is the
radiation-free energy transfer from a donor fluorophore to
a suitable acceptor, and is highly dependent on the distance
between them [40]. This technology enables the determin-
ation of protein-protein interactions in living cells in real
time, and we previously applied this approach to monitor
interactions between ERα and its coregulator SRC-1 [11].
To prevent dilution of any potential FRET signal by en-
dogenous proteins, the experiments were performed in
ERα-negative U2OS cells. Cells were transfected with ERα-
CFP, the catalytic subunit of PKA (PKA-cat)-YFP, and a
non-tagged regulatory subunit of PKA to prevent a consti-
tutive activation of PKA-cat. In addition, cells were trans-
fected with an siRNA targeting AKAP13 or a control
siRNA. When the cells were treated with the PKA-
activating compound forskolin, an increase in FRET signal
was observed, implying an increased interaction between
ERα and PKA-cat. This increase was not observed when
AKAP13 was knocked down, suggesting that the inter-
action was lost.
In addition to the biophysical analyses, co-
immunoprecipitations were performed. To perform
these experiments analogous to the FRET assays, and to
block all ERα activity that may affect protein complex
formation, cells were hormone-deprived for 3 days prior
to onset of the experiment. PKA-RII was immunoprecipi-
tated and its association with ERα and AKAP13 was
assessed (Fig. 2c). Both these factors were enriched in
the PKA-RII IP fraction as compared to IgG control.
Note that the AKAP13 protein levels were decreased
in the supernatant fraction after IP. The PKA-RII
regulatory subunit overlapped with the IgG heavy
chain, preventing us to reliably identify this protein as
Fig. 1 Molecular pathway enrichment in ERαS305P positive tumors. a Tissue microarrays, stained for ERαS305P were analysed and subgrouped into
staining negative (left panel) or positive (right panel) for ERαS305P signal. Expression array data from these subgroups were clustered and
pathway enrichement analyses were performed on the expression array data from each subgroup. b AKAP13 and AKAP95 were found to
be the most significantly enriched pathways
Bentin Toaldo et al. BMC Cancer  (2015) 15:588 Page 5 of 12
a part of the complex. We also performed an immu-
noprecipitation for AKAP13 and again identified ERα
as part of the complex (Fig. 2d). The reciprocal ex-
periment was performed as well, and AKAP13 could
be identified after immunoprecipitating ERα (Fig. 2e).
These data collectively indicate that the interaction of
ERα with the PKA complex is mediated by AKAP13
and AKAP13 is essential for the PKA-mediated
ERαS305 phosphorylation.
AKAP13 expression correlates with a non-favorable
outcome after tamoxifen treatment and with ERαS305P
positivity in breast cancer patients
Our findings indicated that expression of AKAP13 in
tissue culture experiments is essential for the PKA-
induced Serine 305 phosphorylation. Next, we investi-
gated whether AKAP13 levels by themselves correlate
with an unfavorable response to treatment in breast can-
cer patients. Therefore, tumor samples were analyzed, in
Fig. 2 AKAP13 is required for PKA-induced ERαS305 phosphorylation and interacts with ERα and PKA-RII. a siRNA targeting AKAP13 prevents
PKA-induced ERαS305 phosphorylation. MCF-7 breast cancer cells were transfected with an siRNA targeting AKAP13 or a control siRNA, after
which the cells were treated for 1 h with 10 μM forskolin or left untreated. Samples were analysed by SDS-PAGE and Westernblotting, probing
with antibodies detecting AKAP13, ERαS305P, ERα or actin as a loading control. b AKAP13 is required for a forskolin-enhanced ERα/PKA-cat
interaction. Estrogen Receptor-negative U2OS cells were transfected with CFP-tagged ERα, YFP-tagged PKA catalytic subunit and a non-tagged
PKA regulatory RII subunit. In addition, cells were transfected with an siRNA targeting AKAP13 or a control siRNA. Energy transfer from the CFP to
the YFP fluorophore was measured in the same cell before and after 1 h of 10 μM forskolin treatment, and the average value prior to treatment
was set on 1. N > 10. Bars indicate SEM. A student’s T-test was performed; p < 0.05. c, d, e AKAP13, ERα and PKA-RII form a complex. MCF-7 cells
were hormone deprived for 3 days to deplete activated ERα transcriptional processes. Following that, cells were lysed for immunoprecipitations,
directed at PKA-RII (c), AKAP13 (d), ERα (e) or a negative control protein. In addition, input and supernatant (sup) samples were taken. Western
blots were probed with antibodies detecting AKAP13, ERα and PKA-RII
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which patients with metastatic disease were treated with
tamoxifen. Time to tumor progression (TTP) was esti-
mated according to the Kaplan–Meier method for AKAP13
expression, segmenting the continuous variable in two
groups (low and high) with equal numbers of patients
(Fig. 3a). Four different AKAP13 probes were available
from the Agilent 44 K array data, and identical analyses
were performed for all the remaining probes (Additional
file 3: Figure S3). Of these four probes, 3 had significant log
rank tests. In addition, we tested the four different
AKAP13 probes for trend, using the significance of
the coefficient for the continuous AKAP13 variable
(Additional file 4: Table S1) and found a significant
test for trend for probe 1 (p = 0.022). We then com-
pared clinico-pathological characteristics for two sub-
groups (low and high) of this probe, Table 1. AKAP13
high tumours were more often lymph node positive
(p = 0.033) and there was a trend towards negative
progesterone receptor status (p = 0.071). Using a uni-
variate Cox proportional hazard model we found a
hazard ratio of 2.10 for patients with high AKAP13
levels (p = 0.007). Other clinico-pathological character-
istics that were significant in the univariate analysis were
ERα level (HR 0.20, p = 0.0002) and PR status (HR 0.45 p =
0.004) (Additional file 4: Table S2). Combining these vari-
ables in the multivariate analysis resulted in a hazard ratio
for AKAP13 of 1.84 (p = 0.031) (Additional file 4: Table S3).
If AKAP13 is indeed required for the PKA-mediated
Serine 305 phosphorylation in breast cancer patients,
the expression levels of AKAP13 would be expected to
correlate with ERαS305P positivity. Unfortunately, using
multiple antibodies against AKAP13, the IHC signal was
high in most cells with a minimal dynamic window, pre-
cluding a reliable categorization of the samples based on
IHC. Therefore, we resorted to analyzing AKAP13
mRNA expression derived from expression arrays that
were generated from the samples of the metastatic co-
hort, and compared those with the ERαS305P signal as
detected by IHC performed on the same tumors (Fig. 3b).
The slides were scored on the basis of ERα S305P posi-
tivity, after which the mRNA levels of AKAP13 were an-
alyzed. High AKAP13 mRNA levels were found enriched
in the ERα S305P positive subgroup with a p value of
0.06. These data illustrate that AKAP13 mRNA levels
correlate with a poor outcome after tamoxifen treatment
as well as ERαS305 phosphorylation status in breast can-
cer patients. For AKAP95, which did not affect ERαS305
phosphorylation in vitro (Additional file 1: Figure S1),
no correlation between ERαS305P IHC and AKAP95
mRNA levels was found (Additional file 5: Figure S4).
AKAP13 knockdown decreases ERα-responsive gene
expression in PKA-driven tamoxifen-resistant cells
AKAP13 interacts with ERα and is required for ERαS305
phosphorylation. Does AKAP13 knockdown also result in
a decrease of ERα-driven gene expression in tamoxifen-
resistant cells? For this, we generated an MCF-7 derivative
cell line that is tamoxifen-resistant through enhanced
PKA activity. An shRNA was used targeting the regulatory
subunit of PKA, PKA-RIα, as was performed before [9].
Knocking down PKA-RIα activated the PKA pathway, as
shown by a phosphorylation of CREB, and increased
ERαS305P levels (Fig. 4a). Furthermore, while control cells
could be effectively blocked in their cell proliferation using
tamoxifen, this was not the case when PKA-RIα was
knocked down (Fig. 4b). Now that we have established a
PKA-driven tamoxifen resistant cell line, the next question
was whether the agonistic features of tamoxifen could be
blocked by targeting AKAP13. Since PKA activation stim-
ulates cell proliferation both in an ERα-dependent as well
as an ERα-independent fashion [9], interpretation of cell
proliferation in shPKA-RIα cells following siAKAP13 may
Fig. 3 AKAP13 mRNA levels, survival and ERαS305P. a AKAP13 expression levels were analyzed and correlated with progression-free survival of a
cohort of breast cancer patients treated for metastatic disease. b Tumors were stratified on the basis of ERαS305P positivity, the AKAP13 mRNA
levels of each sample were analyzed. A Student’s T-test was performed; p = 0.06
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be challenging. To focus the analysis on ERα-functioning
in the context of PKA-driven tamoxifen resistance, we
therefore decided to perform RT-QPCR for two well-
annotated ERα-responsive genes: TFF1 and XBP1 (Fig. 4c).
For both these genes, shPKA-RIα knockdown greatly in-
creased ERα action. Importantly, siAKAP13 did not affect
TFF1 and XBP1 expression in control tamoxifen-treated
cells, where expression levels were comparable to those
found for the full ERα antagonist Fulvestrant (ICI). In cells
with PKA-RIα knockdown, XBP1 and TFF1 levels were
considerably higher under tamoxifen conditions as com-
pared to Fulvestrant conditions. Targeting AKAP13 how-
ever decreased TFF1 and XBP1 levels in tamoxifen-
treated shPKA-RIα cells, now comparable to those levels
found under Fulvestrant conditions. These data indicate
that activation of PKA increases ERα-driven gene expres-
sion under tamoxifen conditions, which can be reverted
by knocking down AKAP13.
Combining the clinical information and cell bio-
logical analyses confirms that AKAP13 is part of the
same complex as ERα and PKA and describes how
AKAP13 expression is essential for PKA-induced ERαS305
phosphorylation, leading to tamoxifen resistance.
Discussion
Resistance to endocrine treatment is a significant clinical
challenge. Endocrine treatment is exclusively prescribed
to patients with luminal breast tumors that comprise ap-
proximately 70 % of all breast cancer cases. Luminal tu-
mors are typically positive for Estrogen Receptor alpha
(ERα), and are considered to grow dependent on the ac-
tivity of this transcription factor. About 50 % of breast
cancer cases without distant metastatic disease can be
cured by surgery alone [14] and endocrine treatment
would not be essential for this patient subpopulation to
prevent a relapse. The remaining group of patients does
require additional treatment to prevent a relapse and
endocrine treatment achieves this goal in 50 % of these
patients. The remaining group is considered to be resist-
ant to endocrine treatment and would therefore require
alternative drug treatment in order to prevent patient re-
lapse. Importantly, tumors that do relapse on one type
of endocrine treatment, may still respond to alternative
endocrine agents [41]. This implies that cross-resistance
is not an intrinsic feature of anti-estrogen resistance and
matching the right patient with the right drug is key to fur-
ther improving breast cancer patient treatment outcome.
Kinases play a central role in endocrine resistance,
with many (receptor tyrosine) kinases being differentially
expressed or differentially activated in endocrine treat-
ment resistant breast cancer. Examples of these include
EGFR [42], ErbB2 [8], IGF-1R [43], PKA [9] and PAK1
[5, 15]. The current study illustrates that not only global
kinase activity, but also locally confined kinase action,
Table 1 Patient characteristics distributed by AKAP13 status
Variable AKAP 13 low AKAP 13 high P-value




Years (range) 64 (38–85) 61(37–82) 0.211£
WHO type carcinoma
IDC 33 86.8 23 82.1 0.246*
ILC 4 10.5 4 14.3
IDC + DCIS 1 2.6 0 0.0
Unknown 0 0.0 1 3.6
Tumor diameter
<= 20 mm 20 52.6 14 50.0 1.000
>20 mm 18 47.4 14 50.0
Lymph node status
Negative 29 76.3 14 50.0 0.033
Positive 8 21.1 13 46.4
Unknown 1 2.6 1 3.6
Histological gradea
Grade I 9 23.7 12 42.9 0.374*
Grade II 19 50.0 7 25.0
Grade III 10 26.3 8 28.6
Unknown 0 0.0 1 3.6
Estrogen receptor
Low (≥10 % < 75 %) 7 18.4 10 35.7 0.160
High (≥75 %) 30 78.9 18 64.3
Unknown 1 2.6 0 0.0
Progesterone
receptor
Negative 11 28.9 15 53.6 0.074
Positive 26 68.4 13 46.4
Unknown 1 2.6 0 0.0
HER2 status
Negative 30 78.9 27 96.4 0.366
Positive 4 10.5 1 3.6
Unknown 4 10.5 0 0.0
ER305phosporylation
Negative 25 78.1 18 66.7 0.510
Positive 5 15.6 6 22.2
Unknown 2 6.3 3 11.1
P values: patients with unknown values were omitted. P values were
calculated using the Fisher’s exact test, except for *Chi square test for trend
and £ Mann–Whitney U test
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal
carcinoma in situ
aAccording to Bloom and Richardson
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which leads to substrate specificity, can play a role in
endocrine resistance. PKA is considered a highly promis-
cuous kinase with the capacity of phosphorylating 64
substrates identified thus far [44]. To achieve substrate
specificity, PKA localization (via its specific interactions
with AKAPs [27]) and activation (through local cAMP
concentrations [17, 18]) are tightly controlled. In the
studied cohort of breast cancer patients, we found
AKAP95 as well as AKAP13 signaling pathways signifi-
cantly enriched in the ERαS305P positive subpopulation.
While AKAP95 knockdown did not influence PKA-
induced ERαS305P levels in vitro, siRNA targeting AKAP13
did prevent ERαS305 phosphorylation. These data highlight
the necessity for in vitro verification of findings based on
correlations in patient subpopulations before drawing con-
clusions that suggest any causality.
As a model for PKA-mediated ERαS305P phosphoryl-
ation, leading to tamoxifen resistance, we propose the
following order of events (as illustrated in Fig. 5):
AKAP13 interacts with ERα as well with PKA-RII. PKA-
RII forms a complex with PKA-RI and the catalytic sub-
unit of PKA, so that the entire PKA complex is indir-
ectly associated to ERα. This interaction is present in the
absence of PKA activation. When cAMP levels increase,
Fig. 4 AKAP13 is required for tamoxifen-driven gene expression in PKA-activated cells. a Activation of the PKA pathway by shRNA-PKA-RIα. Western
blot analysis of ERαS305P, ERα, phospho-CREB and PKA-RIα. Actin was used as loading control. b PKA-RIα knockdown gives rise to tamoxifen resistance.
Control (white) or PKA-RIα knockdown (black) cells were used. An MTT assay was performed after cells were seeded in hormone-deprived
medium (t = 0) and cultured for a week in the absence or presence of tamoxifen. Error bars indicate SD values from six independent
measurements. c RT-QPCR analyses for Control (left) or shPKA-RIα (right) cells. Cells were hormone-deprived and transfected with siCntrl
(white) or siAKAP13 (black). Three days after transfection, cells were incubated with estradiol (E2), tamoxifen (Tam), Fulvestrant (ICI) or DMSO control
(veh). Expression levels of XBP-1 (top) and TFF1 (bottom) were analysed. Error bars indicate SD values from 3 independent measurements
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cAMP can bind PKA-RI and PKA-RII, so that PKA-cat
is dissociated from the complex. By virtue of the pre-
formed protein complex that is mediated by AKAP13,
the activated PKA-cat can locally act and phosphorylate
ERαS305. When the phosphorylated ERα binds tamoxi-
fen, ERα is selectively targeted to a distinct set of gene
promoters to activate these genes, resulting in tamoxifen
resistance [13].
Previous studies support a role of AKAP13 in ERα biol-
ogy and PKA-mediated tamoxifen resistance. A poly-
morphism in AKAP13 (Lys526Gln) has been described to
correlate with high-risk familial breast cancer [32, 34]. In
addition, AKAP13 has been described to interact with ERα,
enhancing its transcriptional potency [45]. Interestingly,
AKAP13 has also been reported to integrate differen-
tial signalling cascades in addition to PKA, including
14-3-3, Rho, PKC and PKD [27]. AKAP13 brings PKC
and PKD within the same complex, so that PKC can
activate PKD [46]. In addition, PKA activity phos-
phorylates AKAP13, so that 14-3-3 can bind to the
complex [47, 48]. This 14-3-3 association diminishes
the Rho-GEF activity of AKAP13, lowering Rho activ-
ity [48]. Since PKA [15, 49], 14-3-3, PKC [50, 51] and
now AKAP13 (this study) have all been implicated in
tamoxifen resistance, this macromolecular complex
could provide a central function for AKAP13 in tam-
oxifen non-responsiveness, which could potentially be
exploited for pharmacological intervention.
Kinases are promising drug targets in cancer treat-
ment. Still, when subcellular localization and activity are
key determining factors rather than global activation sta-
tus of a kinase, the pharmacological inhibition of the
total kinase pool could potentially result in a signifi-
cantly high level of toxicity. Inhibiting the specific interac-
tions of kinases with their localization-confining factors
may provide a highly specific inhibition of a kinase subset,
while the total pool of such a kinase remains unaffected.
With respect to the current study, the interface between
ERα and AKAP13 could be a suitable drugable interaction,
through which this form of tamoxifen resistance could po-
tentially be inhibited.
Conclusions
Breast cancer stratification on ERαS305 phosphorylation
status led to the identification of AKAP13 as a potential
mediator for this phosphorylation event on ERα. AKAP13
expression levels correlate with response to tamoxifen
treatment in the metastatic setting. Tumors with high
Fig. 5 Model for PKA-mediated ERαS305 phosphorylation and the role of AKAP13 in this process. AKAP13 interacts with ERα as well as
PKA-RII. This way, AKAP13 functions as a scaffolding protein, bringing together the PKA complex and its substrate, ERα. When members
of the seven-transmembrane domain (7TM) receptors/ G protein-coupled receptors (GPCRs) are activated, this results in an activation of
Adenyl Cyclase to generate cAMP. PKA is consequently activated, by the association of the PKA-regulatory subunits with cAMP. Subsequently, the
catalytic subunit can dissociate from the complex and directly phosphorylate ERα at Serine 305. This phosphorylation at ERαS305P results
in the recognition of tamoxifen as an ERα agonist, initiation of tamoxifen-driven gene transcription and consequently tamoxifen resistance
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AKAP13 mRNA levels are enriched for ERαS305P positiv-
ity on IHC. Using cell lines, we have shown that AKAP13
interacts both with ERα and PKA-RII, which enables
PKA-induced ERα phosphorylation and tamoxifen-driven
gene expression in a tamoxifen-resistant cell line with ele-
vated PKA activity. With this, AKAP13 plays a key function
in enabling PKA-induced ERα phosphorylation and is caus-
ally involved in ERαS305P-mediated tamoxifen resistance.
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